 |
|
Phytochemicals may protect cartilage, prevent pain in joints
October 04, 2005Johns Hopkins researchers have discovered that plant-derived compounds known for their ability to protect tissue also appear to block the activity of an enzyme that triggers inflammation in joints. Their findings, based on experiments with human cells in a lab, could lead to new arthritis treatments and better methods of making artificial cartilage.
The discovery was detailed in a paper published in the Sept. 27 edition of Proceedings of the National Academy of Sciences.
The findings came to light while the researchers were studying the wildly different ways in which cells in human blood vessels and joints respond to pressure gradients generated from liquid moving along their surface, a force called shear stress. In cells that line blood vessels, the reaction to shear stress is beneficial: the boosting of phase 2 enzymes that may protect the cells from cancer-causing chemicals and other toxic agents. Yet in joints, the response to high shear stress is potentially harmful: an increase in the levels of COX-2 enzyme, which triggers inflammation and pain, and suppresses the activity of phase 2 enzymes, ultimately causing the death of chondrocytic cells. Healthy chondrocytes are responsible for the smooth functioning of joints. When chondrocytes stop functioning properly, the result can be arthritis.
The divergent responses to shear stress prompted a series of experiments in a Johns Hopkins lab supervised by Konstantinos Konstantopoulos, associate professor of chemical and biomolecular engineering and Agarwal-Masson Faculty Scholar. His team knew that strenuous exercise or heavy exertion of muscles can cause joints to increase the levels of harmful COX-2 enzyme. What would happen, the researchers wondered, if the vulnerable chondrocyte cells in human joints were first exposed to the beneficial phase 2 enzymes?
To find out, the researchers obtained compounds that boost the activity of helpful phase 2 enzymes. They added these phase 2 inducers to a dish containing the chondrocyte cells that are crucial to maintaining healthy joints. After 24 hours, the cells were subjected to a stress test designed to mimic aspects of strenuous exercise on a joint as well as the hydrodynamic environment in a bioreactor designed to generate artificial cartilage.
The results were surprising. "The beneficial phase 2 enzymes somehow seemed to prevent the activation of the inflammatory COX-2 enzyme," said Zachary R. Healy, a doctoral student in Konstantopoulos' lab and lead author of the journal paper. "The phase 2 enzymes inhibited the inflammation and the apoptosis - the cellular suicide we'd observed."
Some prescription drugs like Vioxx keep COX-2 enzyme at bay by temporarily blocking its ability to send the biochemical signals that set off pain and inflammation. When the medication is stopped, however, the stockpiled COX-2 enzyme can resume its damaging ways. Unlike these traditional pain killers, Healy said, the phase 2 enzyme inducers seemed to stop the increasing activity of COX-2 enzyme.
"That means these compounds could be useful as a preventive measure, perhaps before strenuous exercise," Healy said. "This has the potential for stopping pain and inflammation before they start."
Although these experiments appeared to be the first to determine how phase 2 enzyme inducers affect chondrocytes, these compounds have been studied extensively by researchers at the Johns Hopkins School of Medicine. Paul Talalay, the medical school's John Jacob Abel Distinguished Service Professor of Pharmacology, has shown that phase 2 enzymes can detoxify certain cancer-causing agents and damaging free radicals in tissue, including cells that line blood vessels. He has isolated compounds in edible plants that boost production of phase 2 enzymes. These phytochemicals can be found in cruciferous plants, including broccoli.
Talalay provided one of the phase 2 inducers used in Healy's experiments. "This was the first work done in applying these phytochemicals to chondrocytes, which are constantly under the influence of forces because of the way we move our joints," Talalay said. "The phase 2 inducers seemed to counteract the effects of that stress by inhibiting the expression of COX-2 enzyme. It's interesting to think that people may be able to obtain this benefit through dietary components."
By showing a way to ward off inflammation and by providing insights into the effects of shear stress, the new chondrocyte research may also aid tissue engineers who are trying to grow artificial cartilage or seeking to revitalize human cartilage in the lab. This is important because human bodies cannot make new cartilage to replace tissue that's lost to injury or disease.
"More research is needed," said Konstantopoulos, who directed and supervised the experiments. "But these discoveries could provide guidelines for designing an ideal hydrodynamic environment in bioreactors for generating functional cartilage as well as for the treatment of osteoarthritis."
Johns Hopkins University
The divergent responses to shear stress prompted a series of experiments in a Johns Hopkins lab supervised by Konstantinos Konstantopoulos, associate professor of chemical and biomolecular engineering and Agarwal-Masson Faculty Scholar. His team knew that strenuous exercise or heavy exertion of muscles can cause joints to increase the levels of harmful COX-2 enzyme. What would happen, the researchers wondered, if the vulnerable chondrocyte cells in human joints were first exposed to the beneficial phase 2 enzymes?
To find out, the researchers obtained compounds that boost the activity of helpful phase 2 enzymes. They added these phase 2 inducers to a dish containing the chondrocyte cells that are crucial to maintaining healthy joints. After 24 hours, the cells were subjected to a stress test designed to mimic aspects of strenuous exercise on a joint as well as the hydrodynamic environment in a bioreactor designed to generate artificial cartilage.
The results were surprising. "The beneficial phase 2 enzymes somehow seemed to prevent the activation of the inflammatory COX-2 enzyme," said Zachary R. Healy, a doctoral student in Konstantopoulos' lab and lead author of the journal paper. "The phase 2 enzymes inhibited the inflammation and the apoptosis - the cellular suicide we'd observed."
Some prescription drugs like Vioxx keep COX-2 enzyme at bay by temporarily blocking its ability to send the biochemical signals that set off pain and inflammation. When the medication is stopped, however, the stockpiled COX-2 enzyme can resume its damaging ways. Unlike these traditional pain killers, Healy said, the phase 2 enzyme inducers seemed to stop the increasing activity of COX-2 enzyme.
"That means these compounds could be useful as a preventive measure, perhaps before strenuous exercise," Healy said. "This has the potential for stopping pain and inflammation before they start."
Although these experiments appeared to be the first to determine how phase 2 enzyme inducers affect chondrocytes, these compounds have been studied extensively by researchers at the Johns Hopkins School of Medicine. Paul Talalay, the medical school's John Jacob Abel Distinguished Service Professor of Pharmacology, has shown that phase 2 enzymes can detoxify certain cancer-causing agents and damaging free radicals in tissue, including cells that line blood vessels. He has isolated compounds in edible plants that boost production of phase 2 enzymes. These phytochemicals can be found in cruciferous plants, including broccoli.
Talalay provided one of the phase 2 inducers used in Healy's experiments. "This was the first work done in applying these phytochemicals to chondrocytes, which are constantly under the influence of forces because of the way we move our joints," Talalay said. "The phase 2 inducers seemed to counteract the effects of that stress by inhibiting the expression of COX-2 enzyme. It's interesting to think that people may be able to obtain this benefit through dietary components."
By showing a way to ward off inflammation and by providing insights into the effects of shear stress, the new chondrocyte research may also aid tissue engineers who are trying to grow artificial cartilage or seeking to revitalize human cartilage in the lab. This is important because human bodies cannot make new cartilage to replace tissue that's lost to injury or disease.
"More research is needed," said Konstantopoulos, who directed and supervised the experiments. "But these discoveries could provide guidelines for designing an ideal hydrodynamic environment in bioreactors for generating functional cartilage as well as for the treatment of osteoarthritis."
Johns Hopkins University
Cox-2 Enzyme News and Current Cox-2 Enzyme Events RSSCelebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
Celecoxib, the anti-inflammatory medication also known by the trade name Celebrex, has proven to be safe and reduces a specific proliferation measurement of precancerous lesions in the lung, according to a study from The University of Texas M. D. Anderson Cancer Center.
Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer
Researchers in Portugal have discovered that a specific mutation of the COX2 gene seems to play a role in the onset of ovarian cancer, increasing women's susceptibility to developing the disease.
Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
A colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical science should employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.
Painkillers may threaten power of vaccines
With flu-shot season in full swing and widespread anticipation of the HPV vaccine to prevent cervical cancer, a new University of Rochester study suggests that using common painkillers around the time of vaccination might not be a good idea.
COX-2 Inhibitors Significantly Reduce Risk of Cancer
Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.
Use of mon-COX-2-specific NSAIDs halves odds for oral cancer: doubles cardiovascular death risk
An analysis of 20 years of data on the health of over 900 adults has found that long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, cuts the risk for oral cancer in smokers by half.
Long-term aspirin use reduces risk for colorectal cancer
A new report from the Nurse's Health Study finds that regular, long-term aspirin use can significantly reduce the risk of colorectal cancer, as suggested by several earlier studies.
More Cox-2 Enzyme News Articles
| Evidence-Based Studies Yield Pearls.(Brief Article): An article from: Family Practice News by Bruce Jancin This digital document is an article from Family Practice News, published by International Medical News Group on November 15, 2000. The length of the article is 1301 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web... | |
| Improved Non-Steroid Anti-Inflammatory Drugs: COX-2 Enzyme Inhibitors This volume contains the proceedings of the William Harvey Conference held in London, 10-11 October, 1995. It covers the molecular biology and physiological functions of the cyclo-oxygenase enzymes, as well as the experimental and clinical aspects of the recently discovered inhibitors of the inducible cyclooxygenase. Particular attention has been directed at the discussion of the ... |
| © 2008 BrightSurf.com |